Company Filing History:
2 out of 5,267 
2 out of 3 
2 out of 2 
Years Active: 2010-2011
Title: Mark J Evans: Innovator in Hematology
Introduction
Mark J Evans is a notable inventor in the field of hematology, particularly recognized for his contributions to the treatment of paroxysmal nocturnal hemoglobinuria (PNH). He is based in the United States and has made significant strides in developing therapies that improve the quality of life for patients suffering from this rare blood disorder.
Latest Patents
Although Mark J Evans holds 2 patents, his latest work focuses on the treatment of PNH using eculizumab, a humanized monoclonal antibody against C5. This innovative therapy inhibits terminal complement activation and has shown promising results in clinical trials. The preliminary 12-week open-label trial indicated that eculizumab could effectively reduce intravascular hemolysis, stabilize hemoglobin levels, and decrease transfusion requirements in patients.
Career Highlights
Mark J Evans is associated with Alexion Pharmaceuticals, Inc., where he has played a crucial role in advancing treatments for PNH. His research has demonstrated that chronic eculizumab therapy is both safe and effective, leading to improved quality of life for patients.
Collaborations
Throughout his career, Mark has collaborated with esteemed colleagues such as Leonard Bell and Russell P Rother, contributing to the collective knowledge and advancements in the treatment of PNH.
Conclusion
Mark J Evans continues to be a significant figure in the field of hematology, with his work on eculizumab paving the way for better patient outcomes in PNH treatment. His dedication to innovation in medicine exemplifies the impact of research and collaboration in improving healthcare.